According to a new market report published by Lucintel, the future of the diagnostic specialty antibody market looks promising with opportunities in hospitals and diagnostic laboratories. The global diagnostic specialty antibody market is expected to grow with a CAGR of 5% from 2020 to 2025. The major drivers for this market are surge in government investment in diagnostic health care and increase in launch of new and innovative biologic diagnostic kits.
To download report brochure, please go to https://www.lucintel.com/diagnostic-specialty-antibody-market.aspx and click "download brochure" tab from the menu
Diagnostic specialty antibodies help to increase the binding capacity of any type of specific antigenan and prove to be effective as diagnostic tool, evaluating various infectious diseases. In this market, monoclonal antibodies, polyclonal antibodies, and recombinant polyclonal antibodies are the major antibody types. Lucintel forecasts that monoclonal antibodies will remain the largest antibody type segment over the forecast period, as monoclonal antibodies play a vital role in the diagnosis of many infectious and chronic diseases, such as cancer. Also, an increase in the importance of monoclonal antibodies in scientific research for generation is projected to boost this segment over the forecast period.
Within this market, hospitals will remain the largest end user segment over the forecast period. Increase in the number of infectious diseases and rise in prevalence of cancer and HIV infections are likely to boost the segment during the forecast period.
North America will remain the largest region over the forecast period. Recent advancemants in diagnostic specialty antibody diagnostics, reimbursement for disease screening, and improved access to diagnostics are the major drivers of the diagnostic specialty antibody market in North America.
Abcam, Sanofi, Abbott laboratories, Hoffmann-La Roche, Danaher, Bio-Rad Laboratories, Boehringer Ingelheim International, Agilent Technologies, and Aytu BioScience are among the major suppliers in the global diagnostic specialty antibody market.
Lucintel, a leading global strategic consulting and market research firm, has analyzed growth opportunities in the global diagnostic specialty antibody market by antibody type, application, end user, and region. Lucintel has prepared a comprehensive research report titled “Growth Opportunities in the Global Diagnostic Specialty Antibody Market 2020-2025: Trends, Forecast, and Opportunity Analysis.” This Lucintel report serves as a catalyst for growth strategy, as it provides comprehensive data and analysis on trends, key drivers, and directions. The study includes trends and forecast for the global diagnostic specialty antibody market by antibody type, application, end user, and region as follows:
By Antibody Type [Value ($ Million) shipment analysis for 2014 – 2025]:
Monoclonal Antibodies
Polyclonal Antibodies
Recombinant Polyclonal Antibodies
By Application [Value ($ Million) shipment analysis for 2014 – 2025]:
Hepatitis Diagnosis
Tuberculosis Diagnostics
Dengue Diagnostics
Oncology Diagnostics
HIV Diagnostics
Infectious Disease Diagnostics
By End User [Value ($ Million) shipment analysis for 2014 – 2025]:
Hospitals
Diagnostic Laboratories
By Region [Value ($ Million) shipment analysis for 2014 – 2025]:
United States
Canada
Mexico
United Kingdom
Germany
Spain
Italy
France
This more than 150-page research report will enable you to make confident business decisions in this globally competitive marketplace. For a detailed table of contents, contact Lucintel at +1-972-636-5056 or visit us at helpdesk@lucintel.com.
About Lucintel
Lucintel, the premier global Management Consulting and market research firm, creates winning strategies for growth. It offers market assessments, competitive analysis, opportunity analysis, Growth Consulting, M&A, and Due diligence services to executives and key decision makers in a variety of industries. For further information, visit www.lucintel.com.